Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05136092 · ClinicalTrials.gov registry record · NA
A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors
A NA study of Colorectal Tumors, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05136092: Completed NA study of Colorectal Tumors, sponsored by Weill Medical College of Cornell University.
NCT05136092 is a NA study of Colorectal Tumors that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05136092, a NA study of Colorectal Tumors, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a portion of the tissue will be used to measure the abundance of fructose and xylose. The study hypothesis is that the tumors will take up fructose sugar but not xylose sugar. A comparison of the sugar uptake between the tumor and normal tissues from the adjacent intestinal epithelium and smooth muscle and the liver will be conducted. This proposal will confirm that human colorectal cancer tumors can directly absorb dietary sugars, which has never been demonstrated.
Primary Outcome
The abundance of fructose in tumor extracts assessed by mass spectrometry in the morning after the consumption of oral sugar solutions.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Cohort 1: HFCS (fructose) fed
- DIETARY_SUPPLEMENT Cohort 2: D-Xylose (xylose-fed)
Study Locations (1)
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-02-16 |
| Est. Completion | 2024-09-27 |
| Phase | NA |
What the finished NCT05136092 record still lists
NCT05136092 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Colorectal Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cohort 1: HFCS (fructose) fed is the first listed.
NCT05136092 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05136092 about?
NCT05136092 is a clinical study titled "A Pilot Study to Determine Fructose Uptake by Primary Human Colorectal Tumors". This proposed study is designed to investigate the specific uptake of fructose by human colorectal tumors. In this study, subjects with colorectal cancer undergoing surgery will receive an oral sugar solution containing fructose or xylose prior to surgery. The tumor will then be resected, and a port...
What is the current status of trial NCT05136092?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-02-16. Estimated completion is 2024-09-27.
What conditions does trial NCT05136092 study?
This clinical trial studies the following conditions: Colorectal Tumors.
What interventions are being tested in trial NCT05136092?
The interventions under investigation include: Cohort 1: HFCS (fructose) fed (DIETARY_SUPPLEMENT), Cohort 2: D-Xylose (xylose-fed) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05136092?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05136092 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05136092's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI